Cyprumed‘s Oral Delivery Technology Advances to Clinical Stage as MSD Initiates Phase I Trial
CYPRUMED | Oral Peptide Delivery Experts
Clinical-Stage Technology for Enhanced Oral Bioavailability and Reduced Food Effect
With extensive expertise in the delivery of macrocyclic and GLP-1 peptides, we partner with companies across the biopharmaceutical spectrum—from emerging biotechs to global pharma leaders such as Bayer, Boehringer Ingelheim and MSD.
Latest news
September, 2026
January, 2026
Cyprumed announces the appointment of Martin E. Judge as Chief Business Officer, effective immediately.
With deep experience in pharma/biotech licensing, strategy and establishment of partnerships, Martin will play a key role in advancing our mission and executing our strategy. He has a background in life sciences and technologies in areas relevant to the Pharma industry based on his education (PhD in Basic Medical Sciences, New York University) and professional experience in R&D and Business Development at Novo Nordisk.
Welcome to the team!
September – October, 2025
Cyprumed signs feasibility agreements with two additional top 20 pharma companies
Areas of expertise
Cyprumed specializes in innovative oral delivery solutions for peptides such as GLP-1 agonists and Biopharmaceutics Classification System injectable (BCS Class IV) drugs, offering superior tablet formulations for enhanced bioavailability. With its team of experts and network, and its proprietary delivery platform, Cyprumed is at the forefront of the oral drug delivery technology industry. Cyprumed enables the transformation of novel peptides and BCS IV compounds into high-quality oral drug products.
Cyprumed technology
The Cyprumed technology offers advantages over current delivery systems. We offer three oral drug delivery platforms: intestinal and gastric peptide delivery, and oral delivery of Biopharmaceutics Classification System injectable (BCS Class IV) drugs. By selecting the right delivery platform for your compound, we can make your API orally bioavailable.
„Our technology is not only highly efficient, but also easy to produce and scale-up, while fulfilling key regulatory requirements.“
Florian Föger, PhD, CEO
Florian Föger, PhD, CEO
Want to collaborate?
Are you interested in a possible collaboration? Do you have any questions? We look forward to hearing from you!